TrialNature communications2016

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

Jill M Spoerke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.